Research on Eco Animal Health Group PLC (EAH:LON) from Equity Development
ECO Animal Health Group has announced that it has submitted a Marketing Authorisation Application and supporting dossier to the European Medicines Agency (EMA) for ECOVAXXIN® MG, its live poultry vaccine targeting Mycoplasma gallisepticum. ECOVAXXIN® MG is the second ‘late-stage’ vaccine product in ECO’s R&D pipeline submitted for EMA marketing authorisation. If approved, ECOVAXXIN® MG will extend ECO’s poultry vaccine offering alongside ECOVAXXIN® MS and complement Aivlosin®, the Group’s flagship, market-leading antibiotic for the treatment of respiratory and intestinal diseases in both pigs and poultry. This latest development follows progress towards commercial launch in the EU of ECOVAXXIN® MS, the vaccine against Mycoplasma synoviae and the first of the portfolio of products under development, in July 2026. The announcement of Interim Results on 30 November offers the opportunity to review our FY27 outlook; we maintain our Fair Value of 180p/share.
View Full Research